Welcome to our dedicated page for Sarepta Therapeutics, news (Ticker: SRPT), a resource for investors and traders seeking the latest updates and insights on Sarepta Therapeutics, stock.
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is a pioneering biopharmaceutical company primarily engaged in the discovery and advancement of RNA-targeted therapeutics. Headquartered in Cambridge, Massachusetts, Sarepta is dedicated to developing innovative treatments for a range of rare, infectious, and other challenging diseases.
Core Focus: Sarepta’s primary focus is on Duchenne Muscular Dystrophy (DMD), a severe type of muscular dystrophy. The company's lead product candidate, eteplirsen, is designed to skip exon 51 and potentially modify the progression of DMD. Alongside eteplirsen, Sarepta is working on other DMD drug candidates that target different exons.
Innovative Technology: The company leverages proprietary RNA-targeted technology platforms to create novel pharmaceuticals. This technology is pivotal in addressing diseases with high unmet medical needs.
Therapeutic Pipeline:
- DMD Program: Focused on rapidly advancing exon-skipping drug candidates.
- Infectious Diseases: Developing treatments for drug-resistant bacteria and other rare infectious diseases.
Financial Condition and Partnerships: Sarepta collaborates with third-party contractors for the manufacturing of its product candidates. This strategic approach allows the company to focus on innovation and development while ensuring efficient production processes. Despite most of its product candidates being in early developmental stages, Sarepta continues to secure funding and partnerships to support its ambitious research and development goals.
For more information, visit their official website at www.sarepta.com.
Rhea-AI Summary
Sarepta Therapeutics, Inc. (SRPT) will announce its Q4 and full-year 2023 financial results on Feb. 28, 2024. A conference call will follow to discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
-
Rhea-AI Summary
Sarepta Therapeutics (NASDAQ: SRPT) receives Priority Review from the FDA for ELEVIDYS, a treatment for Duchenne muscular dystrophy, aiming to broaden the approved indication and convert accelerated approval to traditional.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.78%
Tags
-
Rhea-AI Summary
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) granted equity awards to 14 individuals as a material inducement to employment. The employees received options to purchase 6,925 shares of Sarepta's common stock and 4,950 restricted stock units. The options have an exercise price of $118.99 per share, with vesting schedules over a four-year period. The RSUs will also vest yearly over a four-year period, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
Rhea-AI Summary
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced positive data from Part B of the MOMENTUM study for SRP-5051, a treatment for Duchenne muscular dystrophy. The data showed substantial increases in dystrophin expression and exon skipping, indicating a favorable benefit-risk profile for SRP-5051.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
-
Rhea-AI Summary
Sarepta Therapeutics (SRPT) has announced the initiation of screening in Study SRP-9003-301, a Phase 3, multi-national, open-label study of SRP-9003 for the treatment of limb-girdle muscular dystrophy Type 2E (LGMD2E/R4). The study will enroll 15 participants aged 4 and older and uses commercially representative process SRP-9003 material. Early results from the SRP-9003 clinical development program have shown significant protein expression and functional benefits, including slowing disease progression, improving mobility, and enhancing the quality of life for individuals with LGMD2E.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
-
News
Rhea-AI Summary
Sarepta Therapeutics, Inc. (SRPT) expects a total net product revenue of $1.145 billion for full-year 2023, with ELEVIDYS net product revenue at $131.3 million for the fourth quarter and $200.4 million for full-year 2023, exceeding consensus. RNA-based PMO net product revenue for the fourth quarter and full-year of 2023 is expected to be $234.3 million and $945.0 million, respectively, surpassing the 2023 full-year guidance of $925 million. The year-end 2023 cash, cash equivalents, restricted cash, and investments balance is approximately $1.7 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.41%
Tags
Rhea-AI Summary
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
-
Rhea-AI Summary
Sarepta Therapeutics, Inc. (SRPT) granted equity awards to 4 individuals hired in December 2023, in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received options to purchase 3,850 shares of Sarepta's common stock and 1,900 restricted stock units. The options have an exercise price of $96.43 per share, with vesting schedules over a four-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
-
Rhea-AI Summary
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has submitted an efficacy supplement to the Biologics License Application for ELEVIDYS to expand its labeled indication for the treatment of Duchenne muscular dystrophy patients. The supplement is supported by results from global clinical studies and has been submitted to the U.S. FDA with a request for Priority Review. Sarepta has also completed the EMBARK postmarketing requirement and submitted the request to FDA for conversion from accelerated approval to traditional approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.18%
Tags
Rhea-AI Summary
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) granted equity awards on November 30, 2023, to 13 individuals as an inducement to employment. The employees received options to purchase 14,250 shares of Sarepta's common stock and 7,350 restricted stock units. The options have an exercise price of $81.28 per share, with vesting schedules over four years, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.89%
Tags
FAQ
What is the current stock price of Sarepta Therapeutics, (SRPT)?
The current stock price of Sarepta Therapeutics, (SRPT) is $127.89 as of January 6, 2025.
What is the market cap of Sarepta Therapeutics, (SRPT)?
The market cap of Sarepta Therapeutics, (SRPT) is approximately 12.2B.
What does Sarepta Therapeutics specialize in?
Sarepta Therapeutics specializes in the discovery and development of RNA-targeted therapeutics for rare, infectious, and other diseases, with a primary focus on Duchenne Muscular Dystrophy (DMD).
What is eteplirsen?
Eteplirsen is Sarepta Therapeutics' lead DMD product candidate, designed to skip exon 51 and potentially modify the progression of Duchenne Muscular Dystrophy.
Where is Sarepta Therapeutics headquartered?
Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
What kinds of diseases is Sarepta working on?
In addition to Duchenne Muscular Dystrophy, Sarepta is developing treatments for rare infectious diseases, including drug-resistant bacteria.
How does Sarepta manufacture its products?
Sarepta uses third-party contractors to manufacture its product candidates, allowing the company to focus on research and development.
What is the primary technology used by Sarepta?
Sarepta uses proprietary RNA-targeted technology platforms to develop its pharmaceutical products.
Are Sarepta's products approved for use?
Most of Sarepta's product candidates are currently in early stages of development and are not yet approved for widespread use.
How can I find more information about Sarepta Therapeutics?
You can find more information by visiting their official website at www.sarepta.com.
Is Sarepta involved in any partnerships?
Yes, Sarepta collaborates with third-party contractors and other entities to support its research and development efforts.
What is the latest news about Sarepta Therapeutics?
For the latest updates and news about Sarepta Therapeutics, please visit their official website or follow their stock news on financial websites.
Sarepta Therapeutics,, Inc.
Nasdaq:SRPT
SRPT Rankings
SRPT Stock Data
12.16B
90.38M
4.38%
92.37%
5.85%
Biotechnology
Pharmaceutical Preparations
United States of America
CAMBRIDGE